Women see more adverse events with chemo; study of Gilead’s breast cancer drug raises doubts

Emerging evidence suggests that women also experience greater toxicity with targeted therapies and immunotherapies. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Voting is now underway for STAT Madness, our bracket-style tournament to find the best innovations in science and medicine. Women see more adverse events with chemotherapy and newer cancer treatments, study finds By Marcus A. Banks Hassan Ammar/AP Emerging evidence suggests that women also experience greater toxicity with targeted therapies and immunotherapies. Read More STAT+: A key study of Gilead's breast cancer drug meets goal, but withheld data raise doubts By Adam Feuerstein Yichuan Cao/Sipa USA via AP Images Gilead chose not to provide any specific data from the Trodelvy study, and it would not say whether the results were clinically meaningful. Read More STAT+: FDA effort to improve clinical trial diversity failed to make a difference for Black patients, study finds By Ed Silverman SAUL LOEB/AFP via Getty Images “It’s a very complicated process to improve trial enrollment,” said study co-author Angela Green. “But we need to induce change.” Read More Sponsor content by STAT Events The STAT Breakthrough Science Summit On March 31, take an inside look at the technologies and procedures set to redefine medicine, and change patient care in the years to come. You'll hear from the CEOs, scientists, entrepreneurs at the forefront of these efforts. Get your pass now, and use your STAT+ subscriber login to unlock a 20% discount. Opinion: Inappropriate march-in actions would jeopardize public-private partnerships that make lifesaving medicines possible By Mark Reisenauer Adobe Using Bayh-Dole march-in rights to lower a drug's price would set a troubling precedent and jeopardize new drug discovery and development. Read More Tuesday, March 8, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser